In particular, in a KRAS-mutated NSCLC model, it has been shown that BETi remodel the cancer immune microenvironment, by reducing tumor-infiltrating Treg and inducing T-helper type 1 lymphocytes [208,209]. The gene discussed is KRAS; the disease is neoplasm.